Interventional Cardiology Devices Market By Product Type (Coronary Stents [Drug-Eluting Stents (DES); Bare-Metal Stents (BMS); Bioresorbable Vascular Scaffolds (BVS)]; Catheters [Angiography Catheters; Guiding Catheters; Balloon Catheters; Percutaneous Transluminal Coronary Angioplasty (PTCA) Balloons (Semi-Compliant Balloons; Non-Compliant Balloons)]; Plaque Modification Devices [Atherectomy Devices; Thrombectomy Devices]; Guidewires; Embolic Protection Devices; Transcatheter Heart Valves; Structural Heart Devices; Other Interventional Devices); By Application (Coronary Artery Disease [CAD]; Valvular Heart Disease; Structural Heart Defects; Other Cardiovascular Conditions); By End-User (Hospitals; Cardiac Catheterization Labs; Ambulatory Surgical Centers); By Geography, Segment Revenue Estimation, Forecast, 2024–2032.

Interventional Cardiology Devices Market Size & Overview

The interventional cardiology devices market was valued at $18.5 billion in 2024 and is expected to reach $30.2 billion by 2030, expanding at a CAGR of 8.3% during the forecast period. This growth is primarily fueled by the increasing prevalence of cardiovascular diseases (CVDs), the rising aging population & the growing demand for minimally invasive procedures.

 

According to the World Health Organization (WHO), cardiovascular diseases are the leading cause of death globally, responsible for approximately 17.9 Mn deaths annually, which accounts for 32% of all global deaths. The rising prevalence of risk factors such as hypertension, diabetes & high cholesterol levels is significantly contributing to the market's expansion. Additionally, advancements in medical technology, including drug-eluting stents, balloon catheters & transcatheter heart valves, are further propelling the adoption of interventional cardiology procedures worldwide.

 

In the United States, the Centers for Disease Control & Prevention (CDC) reports that 1 in 3 adults have some form of cardiovascular disease, contributing to high hospitalizations & healthcare costs. As a result, there is a growing shift toward the use of interventional cardiology devices for early diagnosis and treatment of conditions like coronary artery disease, valvular heart disease & structural heart defects. The demand for advanced cardiovascular devices is expected to remain strong, especially with the increasing focus on improving healthcare access & reducing recovery times through minimally invasive procedures. As healthcare providers & patients alike seek effective and less invasive treatment options, the interventional cardiology devices market is poised for continued growth.

 

Interventional Cardiology Devices Market Dynamics:

Rising Prevalence of End-Stage Heart Failure (ESHF) and Cardiogenic Shock

The increasing incidence of heart failure (HF) and cardiovascular diseases (CVDs) globally is a major driver for the MCS devices market. According to the American Heart Association (AHA), nearly 6.2 million adults in the U.S. were living with heart failure in 2023 & this number is expected to rise due to aging populations and lifestyle-related risk factors such as hypertension, obesit & diabetes. Mechanical circulatory support devices, such as left ventricular assist devices (LVADs) and extracorporeal membrane oxygenation (ECMO), provide life-saving treatment for patients in end-stage heart failure or acute cardiogenic shock, where pharmacological interventions alone are insufficient. The demand for durable LVADs for destination therapy (DT) and bridge-to-transplant (BTT) patients is expected to surge as heart transplant shortages persist.

Advancements in Miniaturized and Less Invasive MCS Devices

Innovations in minimally invasive mechanical circulatory support devices are transforming the market by improving patient outcomes and reducing complications. The development of smaller, fully implantable LVADs like Medtronic's HVAD System and Abbott’s HeartMate 3 LVAD with magnetically levitated (MagLev) technology has led to reduced hemolysis, lower thromboembolic events, and improved durability. Similarly, percutaneous ventricular assist devices (pVADs), such as Abiomed’s Impella series, provide short-term hemodynamic support in high-risk percutaneous coronary interventions (PCI) and acute decompensated heart failure (ADHF), driving adoption in interventional cardiology. These technological advancements are enhancing device safety, extending patient life expectancy & expanding indications, fueling market growth.

 

Market Opportunities

Increasing Adoption of Mechanical Circulatory Support in Emerging Markets

The MCS devices market is witnessing substantial growth potential in emerging economies such as China, India & Brazil, where the burden of cardiovascular diseases is escalating. According to the World Health Organization (WHO), over 80% of cardiovascular deaths occur in low- and middle-income countries, yet access to advanced cardiac support therapies remains limited. With improving healthcare infrastructure, rising disposable incomes, and increased government investments in tertiary cardiac care, demand for short-term and durable MCS devices is expected to grow. For instance, China’s National Medical Products Administration (NMPA) recently approved Abbott’s HeartMate 3 LVAD, expanding access to advanced mechanical circulatory support solutions in the Asia-Pacific region.

Rising Clinical Trials and R&D for Next-Generation Artificial Hearts

The development of next-generation total artificial hearts (TAHs) and advanced ventricular assist devices (VADs) presents lucrative growth opportunities for market players. Companies such as Carmat (France) and SynCardia Systems (U.S.) are conducting pivotal clinical trials for novel biocompatible artificial heart systems, aimed at providing long-term hemodynamic support for patients ineligible for heart transplantation. For example, Carmat’s Aeson® Total Artificial Heart received CE Mark approval in Europe and is undergoing further trials in the U.S. and Japan. Similarly, biodegradable polymer-based MCS devices & gene therapy-based myocardial recovery approaches hold promise for future advancements, attracting significant venture capital and government funding in cardiovascular research.

 

Market Restraints

High Cost of MCS Devices and Limited Reimbursement Policies

The prohibitive cost of mechanical circulatory support devices remains a major barrier to market expansion. Implantable LVADs & TAHs can cost between $100,000 - $250,000 per patient, excluding hospitalization & follow-up care expenses. In emerging markets, the lack of adequate reimbursement coverage further limits patient access. In India, while heart failure-related treatments are covered under government health schemes, LVAD implantation remains unaffordable for the majority of patients due to limited insurance support. Even in developed markets, reimbursement varies across healthcare systems, with out-of-pocket costs acting as a significant deterrent for adoption.

Device-Related Complications and Risk of Infections

Despite technological advancements, thrombosis, bleeding events, infection risks, and pump failure remain key challenges in mechanical circulatory support therapy. LVAD patients, for example, require long-term anticoagulation therapy, which increases the risk of gastrointestinal bleeding & stroke. According to clinical studies, thromboembolic events occur in up to 20% of LVAD recipients, while driveline infections are reported in nearly 30% of cases. Efforts to develop fully implantable wireless-powered VADs aim to address these risks, but widespread adoption is still in its early stages. Until these challenges are mitigated, clinicians may be hesitant to expand the use of MCS devices beyond severe cases, limiting market penetration.

 

Interventional Cardiology Devices Market Segmentation: A Comprehensive Overview

By Product Type

• Coronary Stents

  • Drug-Eluting Stents (DES)

  • Bare-Metal Stents (BMS)

  • Bioresorbable Vascular Scaffolds (BVS)

• Catheters

  • Angiography Catheters

  • Guiding Catheters

  • Balloon Catheters

• Percutaneous Transluminal Coronary Angioplasty (PTCA) Balloons

  • Semi-Compliant Balloons

  • Non-Compliant Balloons

• Plaque Modification Devices

  • Atherectomy Devices

  • Thrombectomy Devices

• Guidewires

• Embolic Protection Devices

• Transcatheter Heart Valves

• Structural Heart Devices

• Other Interventional Devices

 

By Application

• Coronary Artery Disease (CAD)

• Valvular Heart Disease

• Structural Heart Defects

• Other Cardiovascular Conditions

 

By End User

• Hospitals

• Cardiac Catheterization Labs

• Ambulatory Surgical Centers

 

By Region

• North America

• Europe

• Asia-Pacific

• Latin America

• Middle East & Africa

 

Interventional Cardiology Devices Market Segment Analysis: Growth Trends Across Categories

By Product Type:

Leading Segment: Coronary Stents

The coronary stents segment holds the largest market share in the interventional cardiology devices market, accounting for approximately 45% of the total market. Coronary stents, especially Drug-Eluting Stents (DES), are pivotal in treating coronary artery disease (CAD) by improving blood flow and reducing the likelihood of artery restenosis. The increasing prevalence of CAD, driven by an aging population, lifestyle changes & rising cardiovascular risk factors (like hypertension and diabetes), is contributing to the dominance of coronary stents in the market. DES are widely adopted due to their ability to release medication that prevents the narrowing of the artery, making them the most popular choice among coronary stents.

Fastest-Growing Segment: Percutaneous Transluminal Coronary Angioplasty (PTCA) Balloons

The fastest-growing segment in the interventional cardiology market is the PTCA balloon segment, with a compound annual growth rate (CAGR) of around 7-8% from 2024 to 2030. This growth is attributed to the increasing demand for minimally invasive procedures and the rise in patients opting for balloon angioplasty, particularly in less severe cases of CAD or when stent placement is not required. Semi-compliant and non-compliant balloons are being increasingly used due to their enhanced ability to dilate narrowed arteries effectively. Technological advancements in balloon materials & designs, leading to greater efficacy & patient outcomes, are further propelling this segment's growth.

 

By Application:

Leading Segment: Coronary Artery Disease (CAD)

Coronary artery disease remains the largest application segment for interventional cardiology devices, commanding approximately 50% of the market share. This is primarily driven by the high prevalence of CAD globally, fueled by aging populations & lifestyle-related risk factors such as obesity, sedentary behavior, and smoking. The market for interventional devices used in CAD is expected to continue growing as the demand for stents, balloons, and catheters rises for both elective and emergency procedures.

Fastest-Growing Segment: Structural Heart Defects

The fastest-growing application segment is structural heart defects, with a projected CAGR of 6-7%. This growth is driven by the increasing awareness of congenital heart conditions and advances in the treatment of structural heart disease. The rise in the use of transcatheter heart valves (THV) & other structural heart devices, such as devices for patent foramen ovale (PFO) & atrial septal defect (ASD) closures, is contributing to the demand in this sector. Technological advancements, such as minimally invasive valve replacement techniques, are fueling the growth in this application.

 

By End User:

Leading Segment: Hospitals

Hospitals dominate the interventional cardiology devices market, accounting for around 60% of the total market share. Hospitals have extensive infrastructure for advanced cardiology procedures, including high-end catheterization labs, and the ability to cater to critical care patients. The demand for interventional devices in hospitals is driven by the high volume of heart-related procedures, particularly in urban centers and specialized cardiac hospitals.

Fastest-Growing Segment: Ambulatory Surgical Centers (ASCs)

Ambulatory surgical centers (ASCs) are the fastest-growing end-user segment in the interventional cardiology market, with a CAGR of approximately 8%. This growth is driven by the increasing trend of outpatient procedures & minimally invasive treatments. ASCs provide patients with quicker recovery times, lower costs & reduced risks compared to traditional hospital stays, making them an attractive option for both patients & healthcare providers. The rise in elective interventional cardiology procedures, particularly for less complex cases of CAD & valve disease, is contributing to this growth.

 

By Region:

Leading Region: North America

North America holds the largest market share in the interventional cardiology devices market, accounting for approximately 40% of the global market. This is mainly driven by the high prevalence of cardiovascular diseases, technological advancements & the presence of leading medical device manufacturers in the region. The U.S. market, in particular, benefits from a high adoption rate of advanced devices such as drug-eluting stents, PTCA balloons, and transcatheter heart valves.

Fastest-Growing Region: Asia-Pacific (APAC)

The APAC region is the fastest-growing market for interventional cardiology devices, with a projected CAGR of around 8-9%. This growth is fueled by the rapid increase in cardiovascular disease prevalence, improving healthcare infrastructure & rising investments in medical technology. Countries like China & India are seeing rising demand for interventional devices, as healthcare systems are evolving & more patients have access to advanced treatment options. Additionally, a growing aging population & increased focus on healthcare modernization contribute to the growth in this region.

 

Interventional Cardiology Devices Market Report Coverage

Report Attribute	Details
Forecast Period	2024 – 2032
Market Size Value in 2024	USD 18.5 Billion
Revenue Forecast in 2030	USD 30.2 Billion
Overall Growth Rate	CAGR of 8.3% (2024 – 2030)
Base Year for Estimation	2024
Historical Data	2017 – 2021
Unit	USD Billion, CAGR (2024 – 2030)
Segmentation	By Product Type, By Application, By End-User, By Geography
By Product Type	Coronary Stents (Drug-Eluting Stents (DES); Bare-Metal Stents (BMS); Bioresorbable Vascular Scaffolds (BVS)); Catheters (Angiography Catheters; Guiding Catheters; Balloon Catheters; Percutaneous Transluminal Coronary Angioplasty (PTCA) Balloons (Semi-Compliant Balloons; Non-Compliant Balloons)); Plaque Modification Devices (Atherectomy Devices; Thrombectomy Devices); Guidewires; Embolic Protection Devices; Transcatheter Heart Valves; Structural Heart Devices; Other Interventional Devices
By Application	Coronary Artery Disease (CAD); Valvular Heart Disease; Structural Heart Defects; Other Cardiovascular Conditions
By End-User	Hospitals; Cardiac Catheterization Labs; Ambulatory Surgical Centers
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	US, Canada, Germany, China, India, etc.
Market Drivers	Rising prevalence of cardiovascular diseases, increasing adoption of minimally invasive procedures, technological advancements in interventional cardiology devices
Pricing and Purchase Options	Customized options available

 

Key Players in the Interventional Cardiology Devices Market

• Medtronic

• Boston Scientific Corporation

• Abbott Laboratories

• Terumo Corporation

• Cardinal Health

• Braun Melsungen AG

• Biotronik

• Koninklijke Philips N.V.

• Merit Medical Systems

• Asahi Intecc Co., Ltd.

 

Recent Developments

• In May 2024, Abbott Laboratories expanded its interventional cardiology portfolio by launching advanced devices for coronary interventions. These include next-generation drug-eluting stents and catheters designed to improve patient outcomes in coronary artery disease treatments. 

• In August 2023, Medtronic completed the acquisition of Avenu Medical, a company specializing in minimally invasive creation of arteriovenous (AV) fistulas for patients with end-stage renal disease. This acquisition aims to enhance Medtronic's offerings in the interventional space, particularly in vascular access solutions.

• In March 2022, Philips launched a new Intravascular Ultrasound (IVUS) system designed to provide enhanced imaging for coronary interventions. This system aims to improve the accuracy of stent placements & optimize patient outcomes during percutaneous coronary interventions (PCI).

 

Future Outlook

The future outlook for the interventional cardiology devices market remains highly optimistic, driven by the increasing global burden of cardiovascular diseases & the continuous advancements in minimally invasive treatment options. The demand for drug-eluting stents, bioresorbable stents, and transcatheter heart valves is expected to rise as healthcare providers focus on improving patient outcomes & reducing hospital stays. Technological innovations such as robot-assisted interventions, AI-driven imaging & next-generation intravascular ultrasound (IVUS) and optical coherence tomography (OCT) technologies are set to revolutionize interventional cardiology. Additionally, the expansion of ambulatory surgical centers (ASCs) and catheterization labs (cath labs) will enhance accessibility to advanced cardiac procedures. Emerging markets in Asia-Pacific and Latin America are likely to offer significant growth opportunities due to increasing healthcare investments, rising awareness & a growing aging population susceptible to coronary artery disease (CAD). However, regulatory hurdles, high device costs, and reimbursement challenges in some regions may pose obstacles to market expansion. Despite these challenges, ongoing R&D efforts, strategic mergers and acquisitions, and increasing adoption of cutting-edge interventional devices are expected to propel the market forward, making interventional cardiology a key segment in the future of cardiovascular care.